Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Type 1 or Type 2 diabetes for at least 6 months
- People aged between 6 and 75 years old
- People whose HbA1c blood sugar level result is 11% or below (confirm with trial site if unsure what your result means)
- For Segment 1: People currently using both a long-acting (basal) insulin and a short-acting (bolus) insulin by injection, and who either count carbohydrates to calculate doses or use a fixed meal dose — both with a correction dose method
- For Segment 2: People currently using or who have been prescribed a long-acting (basal) insulin
- People using one of the following approved insulin types — long-acting: Glargine (including Rezvoglar, Semglee, Toujeo, Soliqua), Degludec (including Tresiba U-100, Tresiba U-200, Xultophy), or Detemir; short-acting: regular insulin, or rapid or ultra-rapid insulin types such as Aspart, Glulisine, Lispro, Fiasp, or Lyumjev
- People willing to wear a FreeStyle Libre continuous glucose monitor (a small sensor that tracks blood sugar) as directed, and to keep records of insulin doses, meals, and daily activities
- People who own a smartphone that is compatible with the study's requirements
- People willing to sign a consent form allowing their data to be used in the study
- For Segment 1 only: People willing to use a bolus calculator tool to help work out insulin doses
Who may not be able to join:
- People who have other medical conditions or treatments that affect blood sugar control, or serious conditions including psychiatric disorders or alcohol or drug misuse, that the study doctor believes could affect safety or the ability to complete the study
- People with serious diabetes-related complications, including severe kidney disease (eGFR below 45 or currently on dialysis), active advanced eye disease (proliferative retinopathy), or active gastroparesis (a stomach condition affecting digestion)
- People currently taking part in another clinical intervention study
- People who are pregnant or planning to become pregnant during the study period
- People currently using intermediate-acting insulin (NPH), mixed/premix insulin combinations (such as Humulin 70/30, Novolog 70/30, Humalog Mix), or inhaled insulin (such as Afrezza)
- People who have hypoglycemia unawareness (meaning they cannot feel the warning signs when their blood sugar drops too low)
- People receiving insulin through an intravenous (IV) drip, or using a combination of injections and an insulin pump
- People who have significant skin conditions or changes at the area where the glucose sensor would be placed, which could interfere with the device or its readings
- People who have had a diabetic ketoacidosis episode, or a severe low blood sugar episode causing a seizure or loss of consciousness, within the month before joining the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Moshe Phillip, MD, Schneider Children's Medical Center
Phone: 972-545950277
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensor glucose percentage of time in hypoglycemia below 54 mg/dL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.